Molecular and evolutionary perspectives of the renin-angiotensin system from lamprey

Wong, Marty Kwok‐Shing; Takei, Yoshiyuki

doi:10.1016/j.ygcen.2017.01.031

Cited by 7 publications

(5 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The renin-angiotensin system (RAS) was initially described more than a century ago by Tigerstedt and Bergman (1898) using extracts of rabbit’s kidney. The RAS is one of the oldest hormone systems in vertebrate phylogeny, being already observed in vertebrates such as lamprey, and it may have played a key role in the process of adaptation from aquatic to terrestrial ecosystems ( Nishimura, 2017 ; Wong and Takei, 2018 ). Consistent with this, the RAS was initially considered a circulating hormonal system that plays a major role in regulation of blood pressure and sodium and water homeostasis.…”

Section: Introductionmentioning

confidence: 99%

The intracellular renin-angiotensin system: Friend or foe. Some light from the dopaminergic neurons

Labandeira‐Garcia

Valenzuela

Costa-Besada

et al. 2021

Progress in Neurobiology

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

The intracellular renin-angiotensin system: Friend or foe. Some light from the dopaminergic neurons

Labandeira‐Garcia

Valenzuela

Costa-Besada

et al. 2021

Progress in Neurobiology

View full text Add to dashboard Cite

show abstract

“…RAS was first described in 1898, and it has been considered that it contributed to the adaptive process from the aquatic to the terrestrial ecosystems [ 20 ]. Renin, a protease, cleaves angiotensinogen to produce angiotensin I [ 21 ].…”

Section: Ace2: Structure Activity and Biological Functionsmentioning

confidence: 99%

Exploring the Role of ACE2 as a Connecting Link between COVID-19 and Parkinson’s Disease

Angelopoulou

Karlafti

Georgakopoulou

et al. 2023

Life

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) is frequently accompanied by neurological manifestations such as headache, delirium, and epileptic seizures, whereas ageusia and anosmia may appear before respiratory symptoms. Among the various neurological COVID-19-related comorbidities, Parkinson’s disease (PD) has gained increasing attention. Some cases of PD disease have been linked to COVID-19, and both motor and non-motor symptoms in Parkinson’s disease patients frequently worsen following SARS-CoV-2 infection. Although it is still unclear whether PD increases the susceptibility to SARS-CoV-2 infection or whether COVID-19 increases the risk of or unmasks future cases of PD, emerging evidence sheds more light on the molecular mechanisms underlying the relationship between these two diseases. Among them, angiotensin-converting enzyme 2 (ACE2), a significant component of the renin-angiotensin system (RAS), seems to play a pivotal role. ACE2 is required for the entry of SARS-CoV-2 to the human host cells, and ACE2 dysregulation is implicated in the severity of COVID-19-related acute respiratory distress syndrome (ARDS). ACE2 imbalance is implicated in core shared pathophysiological mechanisms between PD and COVID-19, including aberrant inflammatory responses, oxidative stress, mitochondrial dysfunction, and immune dysregulation. ACE2 may also be implicated in alpha-synuclein-induced dopaminergic degeneration, gut–brain axis dysregulation, blood–brain axis disruption, autonomic dysfunction, depression, anxiety, and hyposmia, which are key features of PD.

show abstract

“…RAS components were observed for the first time in kidney extracts more than a century ago [ 33 ], and it is known that RAS is one of the oldest hormone systems in vertebrate phylogeny [ 34 , 35 ]. The RAS was originally considered a circulating hormonal system related to the regulation of blood pressure and sodium and water homeostasis.…”

Section: The Renin-angiotensin Systemmentioning

confidence: 99%

Drugs Modulating Renin-Angiotensin System in COVID-19 Treatment

et al. 2022

View full text Add to dashboard Cite

A massive worldwide vaccination campaign constitutes the main tool against the COVID-19 pandemic. However, drug treatments are also necessary. Antivirals are the most frequently considered treatments. However, strategies targeting mechanisms involved in disease aggravation may also be effective. A major role of the tissue renin-angiotensin system (RAS) in the pathophysiology and severity of COVID-19 has been suggested. The main link between RAS and COVID-19 is angiotensin-converting enzyme 2 (ACE2), a central RAS component and the primary binding site for SARS-CoV-2 that facilitates the virus entry into host cells. An initial suggestion that the susceptibility to infection and disease severity may be enhanced by angiotensin type-1 receptor blockers (ARBs) and ACE inhibitors (ACEIs) because they increase ACE2 levels, led to the consideration of discontinuing treatments in thousands of patients. More recent experimental and clinical data indicate that ACEIs and, particularly, ARBs can be beneficial for COVID-19 outcome, both by reducing inflammatory responses and by triggering mechanisms (such as ADAM17 inhibition) counteracting viral entry. Strategies directly activating RAS anti-inflammatory components such as soluble ACE2, Angiotensin 1-7 analogues, and Mas or AT2 receptor agonists may also be beneficial. However, while ACEIs and ARBs are cheap and widely used, the second type of strategies are currently under study.

show abstract

Molecular and evolutionary perspectives of the renin-angiotensin system from lamprey

Cited by 7 publications

References 35 publications

The intracellular renin-angiotensin system: Friend or foe. Some light from the dopaminergic neurons

The intracellular renin-angiotensin system: Friend or foe. Some light from the dopaminergic neurons

Exploring the Role of ACE2 as a Connecting Link between COVID-19 and Parkinson’s Disease

Drugs Modulating Renin-Angiotensin System in COVID-19 Treatment

Contact Info

Product

Resources

About